26 June 2025 : Clinical Research
Six-Year Outcomes of CABG vs PCI in Diabetic Patients with Multivessel Coronary Disease
Szymon Jonik
ABCDEF 1*, Adam Piasecki DEF 1, Anna Jastrzębska DEF 1, Grzegorz Opolski A 1, Marcin Grabowski A 1, Zenon Huczek A 1, Janusz Kochman A 1
DOI: 10.12659/MSM.948348
Med Sci Monit 2025; 31:e948348
Table 3 Medications on admission and at discharge.
| Medications on admission | Overall (317) | CABG (98) | PCI (219) | P value |
|---|---|---|---|---|
| Statin; n (%) | 286 (90.2) | 87 (88.8) | 199 (90.9) | 0.56 |
| ACE inhibitor; n (%) | 220 (69.4) | 62 (63.3) | 158 (72.1) | 0.11 |
| ARB; n (%) | 58 (18.3) | 21 (21.4) | 37 (16.9) | 0.34 |
| Beta-blocker; n (%) | 249 (78.5) | 78 (79.6) | 171 (78.1) | 0.76 |
| Aspirin; n (%) | 283 (90.1) | 90 (93.8) | 193 (88.5) | 0.15 |
| P2Y12 inhibitors; n (%) | 201 (64.0) | 17 (17.7) | 184 (84.4) | <0.01 |
| Statin; n (%) | 298 (94.9) | 89 (92.7) | 209 (95.9) | 0.24 |
| ACE inhibitor; n (%) | 247 (78.7) | 76 (79.2) | 171 (78.4) | 0.89 |
| ARB; n (%) | 66 (21.0) | 18 (18.8) | 48 (22.0) | 0.51 |
| Beta-blocker; n (%) | 251 (79.9) | 73 (76.0) | 178 (81.7) | 0.25 |
| Loop diuretic; n (%) | 160 (51.0) | 70 (72.9) | 90 (41.3) | <0.01 |
| Aldosterone antagonist; n (%) | 76 (24.2) | 15 (15.6) | 61 (28.0) | 0.02 |
| Metformin; n (%) | 284 (90.4) | 83 (86.5) | 201 (92.2) | 0.11 |
| SGLT-2 inhibitors; n (%) | 295 (93.9) | 88 (91.7) | 207 (95.0) | 0.26 |
| ACE – angiotensin-converting enzyme; ARB – angiotensin receptor blocker; CABG – coronary artery bypass grafting; P2Y12 inhibitors – clopidogrel, prasugrel, ticagrelor; PCI – percutaneous coronary intervention; SGLT-2 inhibitors – sodium-glucose cotransporter-2 inhibitors. | ||||